License was Lipocine’s largest product and service line in fiscal 2024, bringing in $10.90M of $11.20M (97%).
| Product and Service | FY 2021 | FY 2022 | FY 2024 |
|---|---|---|---|
| License | $11.00M | $500.00K | $10.90M |
| Minimum Guaranteed Royalties | $4.05M | — | — |
| Materials | $1.04M | — | — |
| Royalty | — | — | $298.14K |
| Sales Based Royalties | $54.99K | — | — |
| Total | $16.14M | $500.00K | $11.20M |
Lipocine brought in $11.20M from its two product and service lines in fiscal 2024, the year ended December 31, 2024. Lipocine regrouped these lines after fiscal 2022, so the total does not compare directly with that year's $500.00K. License was the largest at $10.90M (97.3%), ahead of Royalty at $298.14K (2.7%).
Lipocine began breaking out Royalty in fiscal 2024, when it brought in $298.14K. Lipocine stopped reporting Minimum Guaranteed Royalties ($4.05M in fiscal 2021), Materials ($1.04M in fiscal 2021) and Sales Based Royalties ($54.99K in fiscal 2021) as separate lines.
Lipocine (LPCN) reports its revenue by product and service. In fiscal 2024, License was its largest product and service line, bringing in $10.90M (97.3% of the total), followed by Royalty at $298.14K (2.7%).
License was Lipocine's largest product and service line in fiscal 2024, bringing in $10.90M, or 97.3% of the $11.20M total across its two product and service lines.
Every figure comes from Lipocine's annual financial filings, as reported. Each line keeps the name Lipocine gives it, and years follow its fiscal calendar.
Lipocine's revenue by product and service goes back to fiscal 2021, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.